Search research articles
Contact Us
Filters
Showing results (61-70 of 76) with videos related to
Page
of 8
Sort By:
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
October 15, 2019
Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis
Suma Babu, Eric A Macklin, Katherine E Jackson, et al.
Neuroimage. Clinical
|
May 21, 2021
Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial
Suma Babu, Baileigh G Hightower, James Chan, et al.
Muscle & Nerve
|
November 21, 2018
A pilot trial of RNS60 in amyotrophic lateral sclerosis
Sabrina Paganoni, Mohamad J Alshikho, Sarah Luppino, et al.
Scientific Reports
|
January 26, 2019
Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach
Robert Kueffner, Neta Zach, Maya Bronfeld, et al.
Advanced Therapeutics
|
October 10, 2022
Classical Complement Pathway Inhibition in a "Human-On-A-Chip" Model of Autoimmune Demyelinating Neuropathies
John W Rumsey, Case Lorance, Max Jackson, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
December 6, 2017
Best practices protocol for the evaluation of bulbar dysfunction: summary recommendations from the NEALS bulbar subcommittee symposium
Gary L Pattee, Emily K Plowman, Benjamin R Brooks, et al.
Muscle & Nerve
|
December 19, 2020
Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial
Michael D Weiss, Eric A Macklin, Courtney E McIlduff, et al.
Muscle & Nerve
|
January 9, 2019
Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyotrophic lateral sclerosis
Gary L Pattee, Emily K Plowman, Kendrea L Focht Garand, et al.
Clinical and Translational Science
|
June 1, 2022
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients
Maurits F J M Vissers, Jules A A C Heuberger, Geert Jan Groeneveld, et al.
The New England Journal of Medicine
|
July 9, 2020
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS
Timothy Miller, Merit Cudkowicz, Pamela J Shaw, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 76) with videos related to
Sort By:
Page
of 8
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
October 15, 2019
Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis
Suma Babu, Eric A Macklin, Katherine E Jackson, et al.
Neuroimage. Clinical
|
May 21, 2021
Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial
Suma Babu, Baileigh G Hightower, James Chan, et al.
Muscle & Nerve
|
November 21, 2018
A pilot trial of RNS60 in amyotrophic lateral sclerosis
Sabrina Paganoni, Mohamad J Alshikho, Sarah Luppino, et al.
Scientific Reports
|
January 26, 2019
Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach
Robert Kueffner, Neta Zach, Maya Bronfeld, et al.
Advanced Therapeutics
|
October 10, 2022
Classical Complement Pathway Inhibition in a "Human-On-A-Chip" Model of Autoimmune Demyelinating Neuropathies
John W Rumsey, Case Lorance, Max Jackson, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
December 6, 2017
Best practices protocol for the evaluation of bulbar dysfunction: summary recommendations from the NEALS bulbar subcommittee symposium
Gary L Pattee, Emily K Plowman, Benjamin R Brooks, et al.
Muscle & Nerve
|
December 19, 2020
Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial
Michael D Weiss, Eric A Macklin, Courtney E McIlduff, et al.
Muscle & Nerve
|
January 9, 2019
Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyotrophic lateral sclerosis
Gary L Pattee, Emily K Plowman, Kendrea L Focht Garand, et al.
Clinical and Translational Science
|
June 1, 2022
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients
Maurits F J M Vissers, Jules A A C Heuberger, Geert Jan Groeneveld, et al.
The New England Journal of Medicine
|
July 9, 2020
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS
Timothy Miller, Merit Cudkowicz, Pamela J Shaw, et al.
Page
of 8